Search

Your search keyword '"Panzara, M. A."' showing total 10 results
Start Over Author "Panzara, M. A." Publisher elsevier bv
10 results on '"Panzara, M. A."'

1. P22 WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses

Author

Tillinger, M., primary, Lake, S., additional, Servais, L., additional, Campbell, C., additional, Xu, X., additional, Hart, A., additional, Haegele, J., additional, Singh, K., additional, Rheinhardt, J., additional, Ghosh, A., additional, Xu, D., additional, Panzara, M., additional, and Li-Kwai-Cheung, A., additional

Published
2023
Full Text
View/download PDF

2. FP.12 Application for primary endpoint qualification of the 95th centile of stride velocity (SV95C) in Duchenne muscular dystrophy

Author

Annoussamy, M., primary, Eggenspieler, D., additional, Seferian, A., additional, Mercuri, E., additional, Straub, V., additional, Muntoni, F., additional, Scoto, M., additional, Poleur, M., additional, Daron, A., additional, Butoianu, N., additional, Mirea, A., additional, Goemans, N., additional, Previtali, S., additional, Tulinius, M., additional, Nascimento, A., additional, Heydemann, P., additional, Panzara, M., additional, Singh, T., additional, Strijbos, P., additional, and Servais, L., additional

Published
2022
Full Text
View/download PDF

4. EP.83Design of a Phase 2/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping

Author

Wagner, K., primary, Cripe, L., additional, Eagle, M., additional, Muntoni, F., additional, Niks, E., additional, Phan, H., additional, Straub, V., additional, Hu, X., additional, Antonijevic, I., additional, Berry, S., additional, Quintana, M., additional, Lake, S., additional, and Panzara, M., additional

Published
2019
Full Text
View/download PDF

5. Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)

Author

Panzara, M., primary, Zhang, J., additional, Rinaldi, C., additional, McClorey, G., additional, Bowman, K., additional, Butler, D., additional, Dodart, J., additional, Frank-Kamenetsky, M., additional, Iwamoto, N., additional, Kothari, N., additional, Lu, G., additional, Mathieu, S., additional, M, M., additional, Melkonian, M., additional, Menon, S., additional, Standley, S., additional, Yang, H., additional, Zhong, Z., additional, Wood, M., additional, and Vargeese, C., additional

Published
2017
Full Text
View/download PDF

7. Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

Author

Lycke, J., primary, Arnold, D.L., additional, Cohen, J.A., additional, Coles, A.J., additional, Confavreux, C., additional, Fox, E.J., additional, Hartung, H.-P., additional, Havrdova, E., additional, Selmaj, K.W., additional, Weiner, H.L., additional, Brinar, V., additional, Giovannoni, G., additional, Stojanovic, M., additional, Lake, S.L., additional, Margolin, D.H., additional, Panzara, M., additional, and Compston, D.A.S., additional

Published
2013
Full Text
View/download PDF

8. Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

Author

Balcer, L.J., primary, Arnold, D.L., additional, Cohen, J.A., additional, Coles, A.J., additional, Confavreux, C., additional, Fox, E.J., additional, Hartung, H.-P., additional, Havrdova, E., additional, Selmaj, K.W., additional, Weiner, H.L., additional, Brinar, V., additional, Giovannoni, G., additional, Stojanovic, M., additional, Cinar, A., additional, Margolin, D.H., additional, Panzara, M., additional, and Compston, D.A.S., additional

Published
2013
Full Text
View/download PDF

9. Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy

Author

Margolin, D.H., primary, Rizzo, M.A., additional, Smith, G., additional, Arnold, D.L., additional, Cohen, J.A., additional, Coles, A.J., additional, Confavreux, C., additional, Fox, E.J., additional, Hartung, H.-P., additional, Havrdova, E., additional, Selmaj, K.W., additional, Weiner, H.L., additional, Brinar, V., additional, Giovannoni, G., additional, Miller, T.A., additional, Stojanovic, M., additional, Twyman, C.L., additional, Lake, S.L., additional, Panzara, M., additional, and Compston, D.A.S., additional

Published
2013
Full Text
View/download PDF

10. Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development

Author

Paola Zaratin, Kathryn E Smith, Alan J. Thompson, G. Comi, M. Panzara, Timothy Coetzee, K. Ramsey, Zaratin, P, Comi, Giancarlo, Coetzee, T, Ramsey, K, Smith, K, Thompson, A, and Panzara, M.

Subjects
0301 basic medicine, Pharmacology, Progressive multiple sclerosis, Biomedical Research, Process management, Drug Industry, education, Multiple Sclerosis, Chronic Progressive, Toxicology, Collective impact, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Alliance, Drug development, Drug Design, Drug Discovery, Humans, Business, Cooperative Behavior, health care economics and organizations, 030217 neurology & neurosurgery
Abstract

The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developing treatments for progressive multiple sclerosis (MS). This innovative model promises to facilitate robust collaboration between industry, academia, and patient organizations and accelerate research towards the overarching goal of developing safe and effective treatments for progressive MS.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results